Browse > Article
http://dx.doi.org/10.5223/pghn.2019.22.6.511

Is the Diagnostic Trial with Proton Pump Inhibitors Reasonable for School Age Children with Gastroesophageal Reflux Symptoms?  

Yang, Jaeeun (Department of Pediatrics, Jeju National University School of Medicine)
Lee, Jieon (Department of Pediatrics, Jeju National University School of Medicine)
Lee, Hyunju (Department of Pediatrics, Jeju National University School of Medicine)
Lee, Juyeon (Department of Pediatrics, Jeju National University School of Medicine)
Youn, Young Mee (Department of Pediatrics, Jeju National University School of Medicine)
Choi, Jae Hong (Department of Pediatrics, Jeju National University School of Medicine)
Kim, Yoon-Joo (Department of Pediatrics, Jeju National University School of Medicine)
Kang, Hyun Sik (Department of Pediatrics, Jeju National University School of Medicine)
Han, Kyoung Hee (Department of Pediatrics, Jeju National University School of Medicine)
Kim, Seung Hyo (Department of Pediatrics, Jeju National University School of Medicine)
Kang, Ki-Soo (Department of Pediatrics, Jeju National University School of Medicine)
Publication Information
Pediatric Gastroenterology, Hepatology & Nutrition / v.22, no.6, 2019 , pp. 511-517 More about this Journal
Abstract
Purpose: On the basis of evidence, we aimed to reevaluate the necessity of the empirical proton pump inhibitor (PPI) trial for children with suspected gastroesophageal reflux disease (GERD). Methods: We analyzed the frequency of GERD in 85 school-age children with gastroesophageal reflux (GER) symptoms, who received 24-hour esophageal pH monitoring and/or upper endoscopy. According to the reflux index (RI), the children were classified into normal (RI <5%), intermediate (5%${\leq}$ RI <10%), or abnormal (RI ${\geq}$10%) groups. Results: Fifty six were female and 29 were male. Their mean age was $12.6{\pm}0.5$ (${\pm}$standard deviation) years (range: 6.8-18.6). The RI analysis showed that the normal group included 76 patients (89.4%), the intermediate group included 6 patients (7.1%), and the abnormal group included 3 patients (3.5%). The DeMeester score was $5.93{\pm}4.65$, $14.68{\pm}7.86$ and $40.37{\pm}12.96$ for the normal, intermediate and abnormal group, respectively (p=0.001). The longest reflux time was $5.56{\pm}6.00$ minutes, $9.53{\pm}7.84$ minutes, and $19.46{\pm}8.35$ minutes in the normal, intermediate, and abnormal group, respectively (p=0.031). Endoscopic findings showed reflux esophagitis in 7 patients. On the basis of the Los Angeles Classification of Esophagitis, 5 of these patients were included in group A, 1 patient, in group B and 1 patient, in group C. Conclusion: The incidence of GERD was very low in school-age children with GER symptoms. Therefore, injudicious diagnostic PPI trials would be postponed until the actual prevalence of GERD is verified in future prospective studies.
Keywords
Gastroesophageal reflux; Proton pump inhibitor; Child; Empirical;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Rosen R, Vandenplas Y, Singendonk M, Cabana M, DiLorenzo C, Gottrand F, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the north american society for pediatric gastroenterology, hepatology, and nutrition and the european society for pediatric gastroenterology, hepatology, and nutrition. J Pediatr Gastroenterol Nutr 2018;63:516-54.   DOI
2 Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E, Liptak G, Mazur L, et al.; North American Society for Pediatric Gastroenterology Hepatology and Nutrition; European Society for Pediatric Gastroenterology Hepatology and Nutrition. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009;49:498-547.   DOI
3 Fass R. Empirical trials in treatment of gastroesophageal reflux disease. Dig Dis 2000;18:20-6.   DOI
4 Bautista J, Fullerton H, Briseno M, Cui H, Fass R. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther 2004;19:1123-30.   DOI
5 Fass R, Fennerty MB, Ofman JJ, Gralnek IM, Johnson C, Camargo E, et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 1998;115:42-9.   DOI
6 Stark CM, Nylund CM. Side effects and complications of proton pump inhibitors: a pediatric perspective. J Pediatr 2016;168:16-22.   DOI
7 De Bruyne P, Christiaens T, Vander Stichele R, Van Winckel M. Changes in prescription patterns of acidsuppressant medications by Belgian pediatricians: analysis of the national database, [1997-2009]. J Pediatr Gastroenterol Nutr 2014;58:220-5.   DOI
8 Johnsson F, Joelsson B, Isberg PE. Ambulatory 24 hour intraesophageal pH-monitoring in the diagnosis of gastroesophageal reflux disease. Gut 1987;28:1145-50.   DOI
9 Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil 2018;24:182-96.   DOI
10 Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172-80.   DOI
11 Bagucka B, Badriul H, Vandemaele K, Troch E, Vandenplas Y. Normal ranges of continuous pH monitoring in the proximal esophagus. J Pediatr Gastroenterol Nutr 2000;31:244-7.   DOI
12 Benmassaoud A, McDonald EG, Lee TC. Potential harms of proton pump inhibitor therapy: rare adverse effects of commonly used drugs. CMAJ 2016;188:657-62.   DOI
13 Neto RML, Herbella FAM, Schlottmann F, Patti MG. Does DeMeester score still define GERD? Dis Esophagus 2019;32:doy118.   DOI
14 MD save. Bravo 48 hour pH monitor [Internet]. San Francisco: MD saves; 2019 [cited 2019 May 7]. Available from: https://www.mdsave.com/procedures/bravo-48-hour-ph-monitor/d784fecc
15 MD save. Upper endoscopy [Internet]. San Francisco: MD saves; 2019 [cited 2019 May 7]. Available from: https://www.mdsave.com/procedures/upper-endoscopy-egd/d782ffc5
16 Yang A, Kang B, Choe JY, Kim HS, Kim K, Choe YH. Prevalence and epidemiological characteristics of endoscopically proven reflux esophagitis in children in Korea. Pediatr Gastroenterol Hepatol Nutr 2017;20:160-6.   DOI
17 Hassall E. Over-prescription of acid-suppressing medications in infants: how it came about, why it's wrong, and what to do about it. J Pediatr 2012;160:193-8.   DOI
18 Streets CG, DeMeester TR. Ambulatory 24-hour esophageal pH monitoring: why, when, and what to do. J Clin Gastroenterol 2003;37:14-22.   DOI
19 Lupu VV, Ignat A, Paduraru G, Ciubara A, Moscalu M, Marginean CO, et al. Correlation between the different pH-metry scores in gastroesophageal reflux disease in children. Medicine (Baltimore) 2016;95:e3804.   DOI
20 Jung HK, Choi MG, Baek MK, Wu JCY. Development and psychometric assessment of a self-evaluation questionnaire for gastroesophageal reflux disease. J Neurogastroenterol Motil 2018;24:584-92.   DOI
21 Gonzalez Ayerbe JI, Hauser B, Salvatore S, Vandenplas Y. Diagnosis and management of gastroesophageal reflux disease in infants and children: from guidelines to clinical practice. Pediatr Gastroenterol Hepatol Nutr 2019;22:107-21.   DOI
22 Taghavi SA, Ghasedi M, Saberi-Firoozi M, Alizadeh-Naeeni M, Bagheri-Lankarani K, Kaviani MJ, et al. Symptom association probability and symptom sensitivity index: preferable but still suboptimal predictors of response to high dose omeprazole. Gut 2005;54:1067-71.   DOI
23 Vandenplas Y, Goyvaerts H, Helven R, Sacre L. Gastroesophageal reflux, as measured by 24-hour pH monitoring, in 509 healthy infants screened for risk of sudden infant death syndrome. Pediatrics 1991;88:834-40.